Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.46 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.45 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856827 | 0.95 | PDE4B (0.44) | TEAD1TEAD3GPR119PARP1ABHD6 | |
| SCHEMBL4856821 | 0.95 | PDE4B (0.44) | TEAD1TEAD3GPR119PARP1ABHD6 | |
| SCHEMBL4859279 | 0.93 | TEAD1 (0.45) | TEAD1TEAD3GPR119PARP1PDE4B | |
| SCHEMBL4859274 | 0.93 | TEAD1 (0.45) | TEAD1TEAD3GPR119PARP1PDE4B | |
| SCHEMBL13340759 | 0.91 | PARP1 (0.58) | TEAD1TEAD3PARP1ABHD6DAGLA | |
| SCHEMBL4860080 | 0.91 | PARP1 (0.58) | TEAD1TEAD3PARP1ABHD6DAGLA | |
| SCHEMBL4860072 | 0.91 | PARP1 (0.58) | TEAD1TEAD3PARP1ABHD6DAGLA | |
| SCHEMBL8237158 | 0.89 | TEAD1 (0.44) | TEAD1TEAD3GPR119PDE4BHRH2 | |
| SCHEMBL6726132 | 0.88 | GPR119 (0.46) | GPR119PARP1ABHD6DAGLANR1H2 | |
| SCHEMBL13705162 | 0.86 | PARP1 (0.57) | GPR119PARP1ABHD6DAGLANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | TEAD1 3386/4885TEAD3 4337/4885GPR119 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.